OXBDF - Oxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: Prelim

Oxford Biomedica (OTCPK:OXBDF) released Wednesday its FY21 preliminary results with revenue of £142.8M (+63% Y/Y). Revenues from bioprocessing and commercial development rose 87% linked to the commercial manufacturing of the adenovirus-based Oxford AstraZeneca COVID-19 vaccine at group's Oxbox facility. Cumulative revenues from AstraZeneca by the end of 2021 were in excess of £100M as expected. Milestones, licences and royalties sales, which included recognition of the £4M license fee from Boehringer Ingelheim, decreased by 25% to £14.4M. Group's Operating EBITDA was £35.9M, comprising of platform division's EBITDA profit of £45.3M (vs. 2020: £13.9M profit) and product division EBITDA loss of £9.4M (vs. 2020: £6.6M loss). Cash generated from operations of £24.5M during the year. As at 31 Dec., cash balance was £108.9M and £144M at 31 Mar. 2022 The company raised £50M through a placing with Serum Life Sciences Ltd in Sept. 2021 to develop the fallow area of the Oxbox manufacturing facility. In March, Oxford Biomedica completed an

For further details see:

Oxford Biomedica reports 63% revenue growth linked to AstraZeneca vaccine supply: Prelim